07.05.2015
RHÖN-KLINIKUM AG DE0007042301
DGAP-News: RHÖN-KLINIKUM AG: Interim Report for the First Quarter of 2015: financial year begins strongly for RHÖN-KLINIKUM AG - research and quality offensive strengthens our market position in cutting-edge healthcare
DGAP-News: RHÖN-KLINIKUM AG / Key word(s): Quarter
Results/Miscellaneous
RHÖN-KLINIKUM AG: Interim Report for the First Quarter of 2015:
financial year begins strongly for RHÖN-KLINIKUM AG - research and
quality offensive strengthens our market position in cutting-edge
healthcare
07.05.2015 / 07:00
---------------------------------------------------------------------
Corporate News
Interim Report for the First Quarter of 2015: financial year begins
strongly for RHÖN-KLINIKUM AG - research and quality offensive strengthens
our market position in cutting-edge healthcare
- 191,730 patients treated
- Revenues stand at EUR 276.1 million
- EBITDA amounts to EUR 49.7 million
- Outlook for 2015: Revenues between EUR 1.08 billion and EUR 1.12
billion,EBITDA between EUR 145 million and EUR 155 million
Bad Neustadt/Saale, 7th May 2015
In the first quarter of the current financial year almost 200,000 (191,730
to be precise) patients were treated in the hospitals of RHÖN-KLINIKUM AG.
Revenues amounted to EUR 276.1 million for the period from January to March
with earnings before interest, taxes, depreciation and amortisation
(EBITDA) standing at EUR 49.7 million. These financial figures are not
directly comparable with those of previous years due to the sale of a total
of 43 facilities which was completed in the last financial year.
Annual General Meeting on 10th June 2015
The Board of Management and Supervisory Board shall propose to this year's
ordinary Annual General Meeting the distribution of the net consolidated
profit in the form of a dividend in the amount of EUR 0.80 per non-par
share to the shareholders. The Company also wishes the shareholders to be
able to participate extensively in subsequent years in the future success
of the Company by means of dividend payout ratios which are clearly above
60 % of the group profit. A precondition is that growth increasing the
value of the Company will not be realised by acquisitions, for example.
We are currently planning to carry out another share repurchase scheme
after the Annual General Meeting through a public purchase offer with a
volume of approx. 10 % of the current share capital. The corresponding
authorisation was already granted by the Annual General Meeting in 2014. A
final decision by the Board of Management and Supervisory Board on the
actual procedure, exact time and financial aspects of the repurchase is
still outstanding. In the course of distributing the sales proceeds the
shareholders already had the opportunity in Autumn 2014 through a share
repurchase programme with subsequent capital reduction to offer their
shares to the Company. With an ultimate offer rate of approx. 98.4 % and
together with last year's dividend roughly EUR 1.7 billion has already been
distributed to the shareholders with this instrument.
Outlook
We expect revenues of EUR 1.08 billion to EUR 1.12 billion and EBITDA of
between EUR 145 million and EUR 155 million for 2015, the first full
financial year with the new portfolio structure. As in 2013 and 2014
one-off effects will continue to influence the corporate results during
this financial year as well. The size of these positive and negative
special influences is a low two-digit million figure; they will be priced
in gradually over the entire financial year 2015 and will partially cancel
each other out.
"We have successfully stayed our course for organic growth in the first
three months of the current financial year. Our focus is on medical
innovations and new therapies as well as modern equipment and procedures
for the benefit of our patients. We are therefore increasing our research
and development budget accordingly in order to strengthen our unique
standing in the market. Innovation projects with a total volume of roughly
EUR 4 million will be financed at all our locations within the corporate
group in the next few months," CEO Dr. Dr. Martin Siebert stated. Since 1st
January 2015 all Group locations either have university hospital status or
act as academic teaching hospitals with a close link to science, research
and training. Furthermore Siebert referred to the fact that the planned
hospital reform envisages payment of medical services based on quality
indications. "We have also done our homework with respect to quality. Our
hospitals will certainly benefit if this criterion does indeed become
relevant for the calculation of fees."
**************************************************************************
RHÖN-KLINIKUM AG AG is one of the largest healthcare providers in Germany.
With ten hospitals in five locations and a total of 5,300 beds we offer
affordable cutting-edge medical care with a direct link to universities and
research institutes. Our facilities are located in Bad Berka, Bad
Neustadt/Saale, Frankfurt (Oder) and Giessen and Marburg. A total of over
15,000 employees work for RHÖN-KLINIKUM AG.
Further information is available at: www.rhoen-klinikum-ag.com.
Your Contact Persons:
RHÖN-KLINIKUM AG
Achim Struchholz
Group Division Head of Corporate Communication
Schlossplatz 1
97616 Bad Neustadt / Saale
Telephone: + 49 - 9771 65-1327
Facsimile: + 49 - 9771 65-1820
E-Mail: [email protected]
Dr. Kai G. Klinger
Group Division Head of Investor Relations & Group Financing
Schlossplatz 1
97616 Bad Neustadt / Saale
Telephone: + 49 - 9771 65-1318
Facsimile: + 49 - 9771 99-1736
E-Mail: [email protected]
---------------------------------------------------------------------
07.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: RHÖN-KLINIKUM AG
Schlossplatz 1
97616 Bad Neustadt a.d.Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: [email protected]
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Munich;
Regulated Unofficial Market in Berlin, Dusseldorf,
Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
354199 07.05.2015
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
RHÖN-KLINIKUM AG ISIN: DE0007042301 können Sie bei EQS abrufen
Pflegeeinrichtungen , 704230 , RHK , XETR:RHK